Teva Pharmaceutical (TEVA) stock
Last close $38.54 on 2026-11-19 (-8.74%) · Sector: Healthcare
Teva Pharmaceutical is an Israeli drugmaker headquartered in Tel Aviv, Israel, with customers around the world. It makes money mainly by selling generic medicines, which are lower-priced copies of brand-name drugs, along with branded prescription medicines.
Teva's revenue has been fairly steady, with the latest quarter at $4.4 billion and revenue growth of 2.6% over the past year. The stock is up 58.7% over the past year, well ahead of the S&P 500's 9.7% gain, though it sits 13.5% below its 52-week high. The stock rose the day after all five recent earnings reports, but insiders sold $32.9 million of shares over the last 90 days and bought none.
Key numbers
- Market cap: $45.6B
- Revenue (last 12 months): $17.22B
- Revenue growth: +2.6%
- Gross margin: 53.4%
- Operating margin: 8.3%
- P/E: 87.6
- P/S: 2.6
- Debt to equity: 3.61
- Current ratio: 0.95
Quality score
Overall 16/100 · growth 32 · profitability 30 · financial health 0 · value 0
Performance and risk
1-year return +58.7% vs S&P 500 +9.7% · volatility 35.0% (S&P 500 13.8%) · largest drop -21.8% · beta 0.71
Stock move the day after earnings
- 2026-01-12: +2.4%
- 2026-01-28: +2.1%
- 2026-04-29: +11.9%
- 2026-07-29: +9.6%
- 2026-11-03: +3.0%
Insider trades (12 months)
Bought $0.0M · sold $125.7M
TEVA stock research · TEVA options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.